-
Metabolix Appoints Stephen J. Large to Board of Directors
Wednesday, March 28, 2012 - 9:02am | 51Metabolix, Inc. (NASDAQ: MBLX) today announced that it has appointed Stephen J. Large to its board of directors. Mr. Large brings more than 25 years of experience in the global chemicals industry to the Company's board. The appointment is effective as of Monday, March 26, 2012.
-
Elagolix Endometriosis Phase III Trials on Track to Commence in Second Quarter 2012
Tuesday, March 27, 2012 - 8:02am | 137Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the United States Food and Drug Administration (FDA) has responded to the Special Protocol Assessment filed with the FDA on the design of the Phase III program for elagolix in endometriosis. The FDA comments on the February 2012 SPA...
-
Neurocrine Announces Phase II Results of VMAT2 Inhibitor NBI-98854 for Treatment of Tardive Dyskinesia
Monday, March 26, 2012 - 4:01pm | 257Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced efficacy and safety results from a Phase II trial of NBI-98854 in 37 tardive dyskinesia patients. For the final analysis, data from one site was removed due to the inconsistent and incorrect application of the efficacy assessment protocol...
-
UPDATE: Deutsche Bank Initiates Buy, $15 PT on Neurocrine
Friday, March 16, 2012 - 6:17am | 80Deutsche Bank initiates its coverage on Neurocrine (NASDAQ: NBIX) with a Buy rating and a price target of $15 as it believes share valuation is underestimated. Deutsche Bank notes, "We rate NBIX shares BUY because currently shares reflect only value to Elagolix in endometriosis & zero to...
-
Metabolix Grants a Patent License to NatureWorks LLC for New Biopolymer Blends
Wednesday, March 14, 2012 - 9:02am | 207Metabolix, Inc. (NASDAQ: MBLX) today announced that it has granted a non-exclusive license to NatureWorks LLC for the U.S. patent No. 5,883,199, titled “Polylactic Acid-based Blends,” to make, use and sell blends of polylactic acid (PLA) with certain other polymers including polybutylene succinic...
-
Earnings Scheduled For March 6
Tuesday, March 6, 2012 - 4:58am | 492Vail Resorts Inc (NYSE: MTN) is expected to report its Q2 earnings at $1.36 per share on revenue of $369.5 million. United Natural Foods Inc (NASDAQ: UNFI) is projected to report its FQ2 EPS at $0.44 per share on revenue of $1.26 billion. Kronos Worldwide Inc (NYSE: KRO) is estimated to post its...
-
Ligand Licenses DARA Program to Retrophin; Potential For Over $75 Million In Milestone Payments to Ligand Plus Royalties
Tuesday, February 21, 2012 - 9:06am | 179Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Retrophin, LLC announced that the companies have entered into an agreement in which Ligand has licensed rights to DARA (a Dual Acting Receptor Antagonist of Angiotensin and Endothelin receptors) to Retrophin. Under the terms of the agreement,...
-
MLV & Co Affirms Ligand Pharmaceuticals Buy, $30 PT
Wednesday, February 8, 2012 - 5:18pm | 108MLV & Co affirms its Buy rating and $30 price target on Ligand Pharmaceuticals (NASDAQ: LGND) following the company's earnings results in a research report out today. In the report, MLV & Co writes, "On February 8, after market close, LGND reported a net gain in 4Q:11 of $4.8M and EPS of $...
-
From Earlier: Ligand Presents Full Data from Successful Phase II Trial of Captisol-Enabled, Propylene Glycol-Free Melphalan
Thursday, February 2, 2012 - 8:24am | 268Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced that results from the Phase II study of its Captisol-enabled, propylene glycol-free (PG-free) Melphalan program were featured this evening in a poster presentation at the combined annual meetings of the Center for International Blood...
-
Neurocrine Biosciences Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares
Monday, January 30, 2012 - 5:00pm | 92Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the closing of the sale of 1,425,000 shares of its common stock pursuant to the exercise in full of an option to purchase such shares granted to the underwriters of Neurocrine's previously announced public offering of common stock that...
-
Neurocrine Biosciences Announces The FDA Has Granted Fast Track Designation For VMAT2 Inhibitor NBI-98854
Wednesday, January 25, 2012 - 9:31am | 105Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that its VMAT2 inhibitor product candidate, NBI-98854, has been granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of neuroleptic-induced tardive dyskinesia. The FDA's Fast Track program is designed...
-
Neurocrine Biosciences Prices Public Offering of Common Stock at $8.10 per Share
Thursday, January 19, 2012 - 10:11am | 79Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of an underwritten public offering of 9,500,000 shares of its common stock at a price to the public of $8.10 per share. The gross proceeds to Neurocrine from this offering, before deducting underwriting discounts and...
-
Neurocrine Biosciences Announces Proposed Public Offering of Common Stock; No Amount given
Wednesday, January 18, 2012 - 5:01pm | 96Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it is offering to sell shares of its common stock in an underwritten public offering. Jefferies & Company, Inc. and Deutsche Bank Securities Inc. are acting as joint book-running managers for this offering, Piper Jaffray & Co...
-
Metabolix Shares Down 55% After JV Termination
Friday, January 13, 2012 - 11:09am | 175Metabolix shares are down more than 55% today after the company announced its joint venture with Archer Daniels had been terminated. Metabolix (NASDAQ: MBLX) announced that the Archer Daniels Midland Company (NYSE: ADM) has given notice of termination of the Telles, LLC joint venture for PHA...
-
Benzinga's Top Pre-Market Losers
Friday, January 13, 2012 - 9:19am | 137Metabolix Inc (NASDAQ: MBLX) shares fell 45.74% to $3.25 in the pre-market trading. Archer Daniels Midland Co (NYSE: ADM) reported that it will end a biodegradable plastics joint venture with Metabolix. JDA Software Group Inc (NASDAQ: JDAS) moved down 14.36% to $28.09 in the pre-market session....